Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes-Reference-Cited by-同舟云学术

Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes

Published:2020-06-30 Issue:7 Volume:9 Page:395-404
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Chen Nianhang¹,Kassir Nastya²,Laadem Abderrahmane¹,Maxwell Stephen E.¹,Sriraman Priya¹,Giuseppi Ana Carolina¹,Ritland Steve¹,Linde Peter G.³,Budda Balasubrahmanyam³,Reynolds Joseph G.³,Zhou Simon¹,Palmisano Maria¹

Affiliation:

1. Bristol Myers Squibb Princeton New Jersey USA

2. Certara Strategic Consulting Princeton New Jersey USA

3. Acceleron Pharma Cambridge Massachusetts USA

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Pharmacology (medical),Modelling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12521

Reference24 articles.

1. Myelodysplastic syndromes

2. Clinical Presentation, Diagnosis, and Prognosis of Myelodysplastic Syndromes

3. Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS

4. Reduced SMAD7 Leads to Overactivation of TGF-β Signaling in MDS that Can Be Reversed by a Specific Inhibitor of TGF-β Receptor I Kinase

5. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population pharmacokinetics of imetelstat, a first‐in‐class oligonucleotide telomerase inhibitor;CPT: Pharmacometrics & Systems Pharmacology;2024-05-21

2. Treatment of refractory or relapsed myelodysplastic neoplasms with luspatercept: a multicenter Chinese study;Annals of Hematology;2023-09-08

3. Novel agents for myelodysplastic syndromes;Journal of Oncology Pharmacy Practice;2021-09-24

4. Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins;Journal of Controlled Release;2021-08

5. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia;Drugs;2021-05-10